Che Ma

Dr. Che Ma

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
CWCheng-Chi Wang
Cheng-Chi Wang
JCJuine-Ruey Chen
Juine-Ruey Chen
YTYung-Chieh Tseng
Yung-Chieh Tseng
CHChe-Hsiung Hsu
Che-Hsiung Hsu
YHYu-Fu Hung
Yu-Fu Hung
CWChi-Huey Wong
Chi-Huey Wong
Recent cases of avian influenza H5N1 and the swine-origin 2009 H1N1 have caused a great concern that a global disaster like the 1918 influenza pandemic may occur again. Viral transmission begins with a critical interaction between hemagglutinin (HA) glycoprotein, which is on the viral coat of influenza, and sialic acid (SA) containing glycans, which are on the host cell surface. To elucidate the role of HA glycosylation in this important interaction, various defined HA glycoforms were prepared, and their binding affinity and specificity were studied by using a synthetic SA microarray. Truncation of the N-glycan structures on HA increased SA binding affinities while decreasing specificity toward disparate SA ligands. The contribution of each monosaccharide and sulfate group within SA ligand structures to HA binding energy was quantitatively dissected. It was found that the sulfate group adds nearly 100-fold (2.04 kcal/mol) in binding energy to fully glycosylated HA, and so does the biantennary glycan to the monoglycosylated HA glycoform. Antibodies raised against HA protein bearing only a single N-linked GlcNAc at each glycosylation site showed better binding affinity and neutralization activity against influenza subtypes than the fully glycosylated HAs elicited. Thus, removal of structurally nonessential glycans on viral surface glycoproteins may be a very effective and general approach for vaccine design against influenza and other human viruses.

31 July 2020 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
DZDaming Zhou
Daming Zhou
HDHelen M. E. Duyvesteyn
Helen M. E. Duyvesteyn
CCCheng-Pin Chen
Cheng-Pin Chen
CHChung-Guei Huang
Chung-Guei Huang
TCTing-Hua Chen
Ting-Hua Chen
KHKuan-Ying A. Huang
Kuan-Ying A. Huang
The COVID-19 pandemic has had an unprecedented health and economic impact and there are currently no approved therapies. We have isolated an antibody, EY6A, from an individual convalescing from COVID-19 and have shown that it neutralizes SARS-CoV-2 and cross-reacts with SARS-CoV-1. EY6A Fab binds the receptor binding domain (RBD) of the viral spike glycoprotein tightly (KD of 2 nM), and a 2.6-Å-resolution crystal structure of an RBD–EY6A Fab complex identifies the highly conserved epitope, away from the ACE2 receptor binding site. Residues within this footprint are key to stabilizing the pre-fusion spike. Cryo-EM analyses of the pre-fusion spike incubated with EY6A Fab reveal a complex of the intact spike trimer with three Fabs bound and two further multimeric forms comprising the destabilized spike attached to Fab. EY6A binds what is probably a major neutralizing epitope, making it a candidate therapeutic for COVID-19.

2 June 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MSMing-Ta Sung
Ming-Ta Sung
YLYen-Ting Lai
Yen-Ting Lai
CHChia-Ying Huang
Chia-Ying Huang
LCLien-Yang Chou
Lien-Yang Chou
HSHao-Wei Shih
Hao-Wei Shih
CMChe Ma
Che Ma
Drug-resistant bacteria have caused serious medical problems in recent years, and the need for new antibacterial agents is undisputed. Transglycosylase, a multidomain membrane protein essential for cell wall synthesis, is an excellent target for the development of new antibiotics. Here, we determined the X-ray crystal structure of the bifunctional transglycosylase penicillin-binding protein 1b (PBP1b) from Escherichia coli in complex with its inhibitor moenomycin to 2.16-Å resolution. In addition to the transglycosylase and transpeptidase domains, our structure provides a complete visualization of this important antibacterial target, and reveals a domain for protein–protein interaction and a transmembrane helix domain essential for substrate binding, enzymatic activity, and membrane orientation.

15 January 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JJJia-Tsrong Jan
Jia-Tsrong Jan
TCTing-Jen Rachel Cheng
Ting-Jen Rachel Cheng
YJYu-Pu Juang
Yu-Pu Juang
HMHsiu-Hua Ma
Hsiu-Hua Ma
YWYing-Ta Wu
Ying-Ta Wu
CWChi-Huey Wong
Chi-Huey Wong
Significance: COVID-19 is a global pandemic currently lacking an effective cure. We used a cell-based infection assay to screen more than 3,000 agents used in humans and animals and identified 15 with antiinfective activity, ranging from 0.1 nM to 50 μM. We then used in vitro enzymatic assays combined with computer modeling to confirm the activity of those against the viral protease and RNA polymerase. In addition, several herbal medicines were found active in the cell-based infection assay. To further evaluate the efficacy of these promising compounds in animal models, we developed a challenge assay with hamsters and found that mefloquine, nelfinavir, and extracts of Ganoderma lucidum (RF3), Perilla frutescens , and Mentha haplocalyx were effective against SARS-CoV-2 infection.

14 February 2020 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
JCJuine-Ruey Chen
Juine-Ruey Chen
YLYo-Min Liu
Yo-Min Liu
YTYung-Chieh Tseng
Yung-Chieh Tseng
CMChe Ma
Che Ma
Vaccination is the most effective measure at preventing influenza virus infections. However, current seasonal influenza vaccines are only protective against closely matched circulating strains. Even with extensive monitoring and annual reformulation our efforts remain one step behind the rapidly evolving virus, often resulting in mismatches and low vaccine effectiveness. Fortunately, many next-generation influenza vaccines are currently in development, utilizing an array of innovative techniques to shorten production time and increase the breadth of protection. This review summarizes the production methods of current vaccines, recent advances that have been made in influenza vaccine research, and highlights potential challenges that are yet to be overcome. Special emphasis is put on the potential role of glycoengineering in influenza vaccine development, and the advantages of removing the glycan shield on influenza surface antigens to increase vaccine immunogenicity. The potential for future development of these novel influenza vaccine candidates is discussed from an industry perspective.

6 April 2022 in Science Translational Medicine
Verified
Journal Article
Open access
HHHan-Yi Huang
Han-Yi Huang
HLHsin-Yu Liao
Hsin-Yu Liao
XCXiaorui Chen
Xiaorui Chen
SWSzu-Wen Wang
Szu-Wen Wang
CCCheng-Wei Cheng
Cheng-Wei Cheng
CWChi-Huey Wong
Chi-Huey Wong
A major challenge to end the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is to develop a broadly protective vaccine that elicits long-term immunity. As the key immunogen, the viral surface spike (S) protein is frequently mutated, and conserved epitopes are shielded by glycans. Here, we revealed that S protein glycosylation has site-differential effects on viral infectivity. We found that S protein generated by lung epithelial cells has glycoforms associated with increased infectivity. Compared to the fully glycosylated S protein, immunization of S protein with N-glycans trimmed to the mono-GlcNAc–decorated state (S MG ) elicited stronger immune responses and better protection for human angiotensin-converting enzyme 2 (hACE2) transgenic mice against variants of concern (VOCs). In addition, a broadly neutralizing monoclonal antibody was identified from S MG -immunized mice that could neutralize wild-type SARS-CoV-2 and VOCs with subpicomolar potency. Together, these results demonstrate that removal of glycan shields to better expose the conserved sequences has the potential to be an effective and simple approach for developing a broadly protective SARS-CoV-2 vaccine.